Defence Therapeutics Inc.
DTC
Classement en actions
#29267
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Prix de l'action
$0.27889602
Dernière synchronisation: 2026-10-19
Capitalisation boursière
$21.14M
Changement (1 jour)
11.76%
Changement (1 an)
-52.35%
Pays
CA
Échange Defence Therapeutics Inc. (DTC)
Catégorie
Healthcare
Ratio P/S pour Defence Therapeutics Inc. (DTC)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Defence Therapeutics Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Defence Therapeutics Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
